All regulatory updates
148 results found
Illinois SB1773 amendment filed (sam003) detailing xylazine exemptions for veterinary/animal-drug and certain professional uses
An Illinois SB1773 committee amendment (sam003), filed 2025-04-01, provides detailed statutory exemption language (new Section 309.1) stating that, notwithstanding the Schedule/Class III scheduling of xylazine, xylazine is not considered a controlled substance when used/handled under specified conditions (including certain licensed veterinarian use for nonhuman species involving FDA-approved animal drugs, use as an API for manufacturing an FDA-approved animal drug, use by licensed certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinarian supervision). Compliance teams should use the amendment text to assess whether current/anticipated xylazine activities would fall under exemptions if SB1773 is enacted.
Nevada Attorney General Opinion No. 2025-01 discusses controlled-substance prescribing/possession authority and registration issues under NRS 453
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation addressing issues involving controlled substances under NRS 453 (Nevada Uniform Controlled Substances Act), including discussion of authorization/registration considerations relevant to prescribing/possession in the context analyzed by the opinion. While not a codified amendment, the opinion can materially affect compliance expectations for regulated practitioners and entities by clarifying legal interpretation applied in Nevada.
Illinois HB0077 proposed to add xylazine to Schedule III and create exemptions for veterinary and related lawful uses (last action Mar 21, 2025)
HB0077 (104th General Assembly) proposes amending the Illinois Controlled Substances Act to schedule xylazine as a Schedule III controlled substance and to establish explicit exemptions for defined lawful activities (e.g., use by licensed veterinarians in professional practice; certain euthanasia technicians; wildlife biologists under veterinary supervision; other specified lawful uses). The bill status page shows last action on 2025-03-21 (re-referred to Rules Committee). If enacted, regulated entities (veterinary practices, suppliers, facilities handling xylazine) would need to implement controlled-substance handling controls unless covered by an exemption.
OEHHA adds vinyl acetate to the Proposition 65 list as a chemical known to cause cancer (warnings enforceable starting Jan 3, 2026)
OEHHA listed vinyl acetate under Proposition 65 as a chemical known to cause cancer (listing effective January 3, 2025). The Prop 65 warning requirement for significant exposures becomes enforceable starting January 3, 2026 (one-year grace period typical for new listings). Compliance teams should assess products/operations that may expose California consumers/workers to vinyl acetate and implement compliant Prop 65 warnings and related substantiation/documentation before the enforceability date.
Illinois HB2804 proposed fentanyl-specific offenses/penalties including Class X felony for selling/dispensing fentanyl-containing drugs and enhancements for certain fentanyl presentations (referred to House Rules Feb 6, 2025)
HB2804 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act (including Sections 401 and 401.1 per the bill materials) to create/expand fentanyl-specific criminal provisions. The introduced bill materials describe Class X felony treatment for knowingly/unlawfully selling or dispensing any scheduled drug containing a detectable amount of fentanyl, an additional felony for using an electronic communication device in furtherance of trafficking involving fentanyl, and additional sentencing provisions for specified fentanyl/carfentanil amounts and presentations. The ILGA status page shows last action 2025-02-06 (referred to House Rules Committee).
Illinois SB1773 introduced to schedule xylazine as Class III controlled substance; bill text states effective Jan 1, 2026 (proposal)
SB1773 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to schedule xylazine as a Class III controlled substance; the bill PDF synopsis states an effective date of 2026-01-01. An amendment document was also identified that adds xylazine exemption language (e.g., circumstances where xylazine would not be considered a controlled substance). Stakeholders should monitor because scheduling would create new controlled-substance compliance obligations for entities handling xylazine unless exempted.
Illinois SB1553 proposed to add xylazine to Schedule III and add provisions/penalties related to manufacture/delivery/possession with intent (introduced 2025)
SB1553 (104th General Assembly) proposes amending the Illinois Controlled Substances Act to add xylazine to the Schedule III controlled substances list and to establish additional provisions addressing xylazine (including a veterinarian-related provision described in the introduced bill text, and penalty-related amendments tied to manufacture/delivery/possession-with-intent). If enacted, it would extend controlled-substance compliance obligations to xylazine in Illinois, affecting veterinary supply chains and any entities handling xylazine outside the scope of professional-practice exceptions.
ILPMP newsletter summarizes Public Act 103-1064 tightening documentation/court order requirements for access to confidential Prescription Monitoring Program (ILPMP) data; effective Feb 7, 2025
An ILPMP newsletter (Feb 2025) reports that Public Act 103-1064 (effective 2025-02-07) was incorporated into the Illinois Controlled Substances Act and imposes stricter prerequisites for law-enforcement/authorized requestors seeking confidential ILPMP data. The newsletter describes requirements including a reason-to-believe standard, that the request be reasonably related to an investigation, and that a valid court order or subpoena be provided (with limitations described for administrative subpoenas). It also notes the prior online law-enforcement request portal is no longer available. This is compliance-relevant for agencies and entities requesting ILPMP data and for program administrators handling disclosures, as request intake, documentation review, and disclosure procedures must align with the updated statutory requirements.
EPA announces automatic addition of nine PFAS to the TRI list effective Jan 3, 2025 (Reporting Year 2025)
EPA (via EPCRA SERC/TERC Update) announced the automatic addition of nine PFAS to the Toxics Release Inventory (TRI) list effective January 3, 2025. This expands the PFAS subject to TRI reporting and impacts covered facilities’ chemical tracking and TRI Form R/Form A reporting for Reporting Year 2025 (with forms due July 1, 2026, as stated in the update). Compliance teams at TRI-covered facilities should update chemical inventories, supplier declarations, and reporting systems to ensure these PFAS are captured for applicable release and waste management reporting.
Commission opens infringement procedure against Cyprus for failure to transpose RoHS Delegated Directive (EU) 2024/1416 (cadmium LED exemption narrowed)
The European Commission initiated an infringement procedure (letter of formal notice) against Cyprus for not transposing Commission Delegated Directive (EU) 2024/1416, which amends the RoHS Directive (2011/65/EU) by narrowing the scope of a cadmium-related exemption for certain LED applications due to technical progress. This signals heightened enforcement attention on Member State transposition of RoHS delegated directives, which can affect consistent EU market access and national enforcement posture.
POPRC-20 follow-up: Secretariat invites comments/information on listed PFAS and draft risk profile packages (2025 deadlines)
The POPRC-20 follow-up page compiles official Secretariat invitations for comments and information that support the POPRC technical evaluation process for potential Stockholm Convention listings and related documentation. Items highlighted in the research include (i) an invitation dated 22 January 2025 for comments on indicative lists and explanatory notes relating to long-chain PFCAs, PFOA, and PFHxS (deadline shown on the page as 9 June 2025) and (ii) an invitation dated 10 March 2025 for comments on the draft risk profile for PBDD/Fs and mixed PBCDD/Fs (deadline shown as 14 April 2025). For compliance teams, these consultations signal potential future listing actions and evolving scope/interpretation for PFAS and brominated dioxin/furan substances under the Convention process.
ECHA updates REACH SVHC Candidate List: five substances added and one existing entry updated (total 247 entries)
On 21 January 2025, ECHA updated the REACH SVHC Candidate List by adding five hazardous chemicals and updating one existing entry, bringing the Candidate List total to 247 entries. This update is relevant for REACH SVHC compliance because Candidate List additions/entry updates can affect Article 33 communication requirements for SVHCs in articles above 0.1% w/w, associated supply-chain information flows, and other Candidate List-related obligations referenced by ECHA. Compliance teams should review the specific substances/entry update in the ECHA notice and validate substance identifiers and any revised concern information against the authoritative Candidate List table.
Illinois HB1038 proposed to increase fentanyl penalties under 720 ILCS 570/401 and 720 ILCS 570/401.1 (stalled in House Rules as of Jan 9, 2025)
HB1038 (104th General Assembly) proposes amendments to 720 ILCS 570/401 and 720 ILCS 570/401.1 to increase fentanyl-related penalties (including reclassification and sentencing changes for certain fentanyl quantities and enhancements when fentanyl is present). The ILGA bill status page shows the most recent action as 2025-01-09 (referred to the House Rules Committee). While not enacted per the provided sources, it remains a relevant proposed change for stakeholders monitoring potential future fentanyl penalty increases under the Illinois Controlled Substances Act.
PFAS Regulation in Massachusetts: TURA Reporting and Phased Elimination
Massachusetts manages PFAS through a dual-track system. Under TURA, industrial facilities exceeding specific thresholds must track and report their use of listed PFAS categories. Concurrently, new state legislation has established a phased approach to eliminating intentionally added PFAS from consumer goods and industrial discharges to protect environmental justice populations and municipal water systems. The employee notification deadline is January 1, 2026; TURA reporting and planning are due by July 1, 2026; intentionally added PFAS in specified product categories were subject to elimination as of January 1, 2026; and sales of firefighter turnout gear containing PFAS are prohibited beginning in 2027.
NIOSH issues science policy recommending individual quantitative fit-testing for hearing protection, superseding prior derating guidance
NIOSH published an official science policy update recommending employers use individual, quantitative fit testing to evaluate the actual attenuation achieved by workers using hearing protection devices. The policy states it supersedes NIOSH’s earlier hearing protector derating guidance in the 1998 Criteria for a Recommended Standard—Occupational Noise Exposure. This guidance is relevant for occupational hearing conservation programs that previously relied on NRR-based derating assumptions and may drive updates to internal program practices (e.g., adoption of Personal Attenuation Rating (PAR)-based verification).
Washington Legislature bill SB 6281 proposes cloud-service procurement assessment criteria referencing SEC-01 (including future amendments)
Washington State SB 6281 (2025–26 biennium) includes proposed language that would require an assessment prior to purchase of third-party commercial cloud computing services, including evaluation of cybersecurity and regulatory compliance criteria tied to the 'Washington state cybersecurity program policy' (SEC-01) and any subsequent amendments. This is not an amendment to SEC-01 itself, but it would elevate SEC-01 as a statutory reference point for procurement/compliance assessments if enacted.
WaTech adopts SEC-01 Washington State Cybersecurity Program Policy (replacing IT Policy 141 and portions of IT Standard 141.10)
Washington Technology Solutions (WaTech) published the SEC-01 Washington State Cybersecurity Program Policy, adopted by the State CIO and approved by the Technology Services Board on Dec. 10, 2024. The policy replaces legacy statewide security artifacts (IT Policy 141 and specified sections of IT Standard 141.10) and establishes core agency obligations including maintaining an agency cybersecurity program with at least annual review and providing annual agency head/CIO attestation of compliance to WaTech, plus requirements to align vendor/partner contract language with state and agency security requirements.
WaTech issues SEC-01 Washington State Cybersecurity Program Policy replacing portions of IT Standard 141.10 (sections 1.1 and 2.1–2.5)
WaTech/OCIO adopted and the Technology Services Board (TSB) approved SEC-01 “Washington State Cybersecurity Program Policy” (State CIO Adopted and TSB Approved: Dec. 10, 2024). The policy explicitly states it replaces IT Policy 141 and replaces specified portions of IT Security Standard 141.10 (sections 1.1 and 2.1–2.5, originally effective Nov. 13, 2017). Compliance teams tracking OCIO Standard 141.10 should update their control mapping and internal governance documentation to reflect that these sections are now governed by SEC-01 (including program documentation review cadence and enterprise cybersecurity program requirements).
OEHHA adopts amendments to Proposition 65 'clear and reasonable warnings' regulations (short-form warnings changes effective Jan 1, 2025)
OEHHA adopted amendments to the Proposition 65 'clear and reasonable warnings' safe-harbor regulations, including updates impacting use and content of short-form warnings (e.g., requiring identification of at least one listed chemical). The amendments are effective January 1, 2025. Compliance teams should update labeling/artwork, online warnings, and related procedures to meet the amended safe-harbor content requirements and transition provisions.
EPA proposes 2026 NPDES Multi-Sector General Permit (MSGP) with report-only PFAS indicator monitoring for certain sectors
EPA’s Proposed 2026 NPDES Multi-Sector General Permit (MSGP) fact sheet includes a new provision for certain industrial sectors to conduct quarterly, report-only indicator analytical monitoring for PFAS. The fact sheet references monitoring for a suite of PFAS compounds aligned with EPA Method 1633, with analysis using EPA Method 1633. Facilities that rely on MSGP coverage should evaluate whether their sector would be subject to PFAS monitoring and prepare for potential sampling/lab capacity and internal reporting workflows if finalized.